Glick S D, Maisonneuve I M, Pearl S M
Department of Pharmacology and Neuroscience, Albany Medical College, NY 12208, USA.
Brain Res. 1997 Feb 28;749(2):340-3. doi: 10.1016/S0006-8993(96)01414-X.
Ibogaine, a putatively anti-addictive alkaloid, binds to kappa-opioid and NMDA receptors. In the present study we investigated the roles of kappa-opioid and NMDA actions in mediating ibogaine's (40 mg/kg, i.p.) behavioral and neurochemical effects in rats. A combination of a kappa-opioid antagonist (norbinaltorphimine, 10 mg/kg, s.c.) and a NMDA agonist (NMDA, 20 mg/kg, i.p.) partially prevented ibogaine-induced inhibition of intravenous morphine self-administration and ibogaine-induced antagonism of morphine-induced locomotor stimulation. The combination, as well as norbinaltorphimine and NMDA alone, blocked the acute effects of ibogaine on dopamine release and metabolism in the striatum. The data suggest that both kappa-opioid agonist and NMDA antagonist actions of ibogaine contribute to its putative anti-addictive effects.
伊波加因是一种被认为具有抗成瘾作用的生物碱，它能与κ-阿片受体和N-甲基-D-天冬氨酸（NMDA）受体结合。在本研究中，我们调查了κ-阿片受体和NMDA作用在介导伊波加因（40毫克/千克，腹腔注射）对大鼠行为和神经化学效应中的作用。κ-阿片受体拮抗剂（诺宾那托啡，10毫克/千克，皮下注射）和NMDA激动剂（NMDA，20毫克/千克，腹腔注射）联合使用部分阻止了伊波加因诱导的静脉注射吗啡自我给药抑制以及伊波加因诱导的吗啡诱导的运动刺激拮抗作用。该联合用药以及单独使用诺宾那托啡和NMDA均阻断了伊波加因对纹状体中多巴胺释放和代谢的急性效应。数据表明，伊波加因的κ-阿片受体激动剂和NMDA拮抗剂作用均有助于其假定的抗成瘾作用。
